ESMO2016 Eye on ESMO: Day 2 - gamechangers take centre stage Novartis’ phase 3 advanced breast cancer therapy ribociclib shows promise
ESMO2016 Eye on ESMO: Day 1 - Access in spotlight before data deluge Europe's biggest cancer conference ESMO is underway
Partner Content Partner Content On Demand: The Top 5 Challenges in Immuno-Oncology Trials In the battle against cancer, immunotherapy is proving to be one of the most promising avenues of research.
Articles A breakthrough in lung cancer - the biggest prize in immunot... AstraZeneca/MedImmune hopes its immunotherapy combinations will help it catch up with leaders.
News Lilly bags FDA okay for Wegovy pill rival orforglipron Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
